Sylvie Giacchetti
3PUBLICATIONS
37CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Aug 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.Enora Laas, Anne-Sophie Hamy, Thomas Bachelot
|Feb 01, 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.Patricia A Ganz, Hanna Bandos, Tanja Španić
|May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.Thomas Bachelot, Paul Cottu, Sylvie Chabaud
Pageof 1
Frequent Collaborators
2 joint publications
Suzette Delaloge
2 joint publications
Anne-Claire Hardy-Bessard
2 joint publications
Frederique Penault-Llorca
2 joint publications
Jerome Lemonnier
2 joint publications
David Cameron
1 joint publications
Thomas Bachelot
1 joint publications
Paul Cottu
1 joint publications
Laurence Venat Bouvet
1 joint publications
Apurna Jegannathen
1 joint publications
Judith Bliss
